Dow, S&P 500, Nasdaq end at records on vaccine, stimulus hopes | Inquirer Business

Dow, S&P 500, Nasdaq end at records on vaccine, stimulus hopes

/ 06:12 AM December 18, 2020

wall street us stocks

Wall Street sign at the New York Stock Exchange (NYSE) on December 9, 2020 in New York City. (Photo by Angela Weiss / AFP)

NEW YORK – Wall Street stocks surged to fresh records Thursday, fueled by optimism about the 2021 outlook as coronavirus vaccines advance and Congress appears close to a deal on stimulus spending.

All three major indices ended at all-time highs, with the Dow Jones Industrial Average up 0.5 percent to 30,303.37.

Article continues after this advertisement

The broad-based S&P 500 gained 0.6 percent, ending at 3,722.48, while the Nasdaq Composite Index jumped 0.8 percent to 12,764.75, finishing at a record for the third straight session.

FEATURED STORIES

The records came despite some increasing signs of economic distress in the wake of the latest rise in coronavirus cases.

And data Thursday showed an unexpected jump in jobless claims after a report earlier in the week revealed a drop in retail sales.

Article continues after this advertisement

Investors also shrugged off the latest grim figures on the US coronavirus outbreak, with more than 3,700 deaths and more than 250,000 new Covid-19 cases in 24 hours, according to Johns Hopkins University.

Article continues after this advertisement

Still, markets charged higher as long-stalled congressional talks on stimulus appeared to be entering the home-stretch and US experts met to discuss a Covid-19 vaccine from Moderna expected to lead to imminent regulatory approval.

Article continues after this advertisement

“The market is really showing some great resilience to selling pressure,” said Briefing.com analyst Patrick O’Hare.

“The market is seeing bad data… yet it still rallies because it still is fixated on a 2021 recovery.”

Article continues after this advertisement

Among individual companies, Moderna jumped 5.1 percent as its vaccine candidate neared regulatory approval following earlier approval of a Pfizer-BioNTech vaccine.

The small Massachusetts-based biotech firm teamed up with scientists from the US National Institutes of Health on the product and has received more than $2.5 billion from the US government for its efforts.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Meanwhile, Tesla jumped 5.3 percent in its latest surge ahead of its debut next week as part of the prestigious S&P 500 index.

gsg
TAGS: Dow, NASDAQ, s&p 500, Stock Market, vaccine, Wall Street

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.